(LH) Laboratory of America - Ratings and Ratios

Labcorp Holdings Inc., trading under the ticker symbol LH on the NYSE, stands as a pivotal player in the healthcare diagnostics and laboratory services sector. The company operates through two primary segments: Diagnostics Laboratories and Biopharma Laboratory Services. Its core offerings encompass a wide array of clinical laboratory tests, including blood chemistry analyses, urinalyses, and blood cell counts, alongside specialized tests for conditions such as thyroid function, diabetes (hemoglobin A1C), and vitamin D levels. The company also conducts tests for prostate-specific antigens, sexually transmitted diseases, hepatitis C, and microbiology cultures. Additionally, Labcorp provides substance-abuse testing and alcohol screening services.

Labcorp’s specialty testing services extend into advanced diagnostic areas such as genetic and esoteric testing. These services include anatomic pathology and oncology, cardiovascular disease monitoring, coagulation testing, diagnostic genetics, endocrinology, infectious disease testing, womens health, and pharmacogenetics. The company also offers parentage and donor testing, occupational testing services, medical drug monitoring, chronic disease management programs, and kidney stone prevention tests. Furthermore, Labcorp provides health and wellness services to employers and managed care organizations (MCOs), positioning itself as a comprehensive solution provider in the healthcare ecosystem.

Beyond its core laboratory services, Labcorp has developed a suite of digital tools. These include online and mobile applications that allow patients to access their test results, as well as platforms for healthcare providers, MCOs, and accountable care organizations to streamline workflows. The company also offers specimen collection services and provides drug development, medical device, and companion diagnostic development solutions. Its client base spans pharmaceutical, biotechnology, and medical device companies, as well as MCOs, employer plans, governmental agencies, physicians, hospitals, contract research organizations, academic institutions, and retailers.

Founded in 1995 and headquartered in Burlington, North Carolina, Labcorp has established itself as a key player in the healthcare services industry. Its strategic position at the intersection of clinical diagnostics, drug development, and digital health solutions makes it a critical infrastructure provider for the broader healthcare system. With a market capitalization of $20.42 billion, the company operates on a global scale, supporting clinical trials, drug development, and routine diagnostics for millions of patients annually. Labcorp’s financial profile includes a P/E ratio of 27.70, a forward P/E of 15.41, a price-to-book ratio of 2.54, and a price-to-sales ratio of 1.61, providing investors with a range of metrics to evaluate its valuation and growth prospects.